Distance-based β-amyloid protein detection on PADs for the scanning and subsequent follow-up of Alzheimer's disease in human urine samples

• Published in: Analyst (London) Vol. 147; no. 4; pp. 695 - 73
• Main Authors: Khachornsakkul, Kawin, Tiangtrong, Anongnat, Suwannasom, Araya, Sangkharoek, Wuttichai, Jamjumrus, Opor, Dungchai, Wijitar
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 14.02.2022
• Subjects: Alzheimer Disease - diagnosis; Alzheimer's disease; Amyloid beta-Peptides; Follow-Up Studies; Human wastes; Humans; Indicators and Reagents; Monitoring; Proteins; Reagents; Reproducibility of Results; Urine
• ISSN: 0003-2654; 1364-5528
• DOI: 10.1039/d1an01605a

We report on the first development of a simple distance-based β-amyloid (Aβ) protein quantification using a paper-based device (dPAD) to screen for Alzheimer's disease (AD) and to subsequently follow up on its influence, i.e. , clinical dementia. This sensor method is based on the transformation of a free acid form and its binding with a basic form of bromocresol purple (BCP) through its electrostatic interaction with an Aβ protein. This sensor can measure the length of color change from yellow to blue-green on a paper strip, with this change proportional to the amount of Aβ protein level. We found that the linearity for Aβ protein monitoring was in the range from 0.50 to 10.0 ng mL −1 , and the subsequent naked-eye detection limit for Aβ was 0.20 ng mL −1 . This system also provided high reproducibility and with no apparent interference effect for Aβ protein analysis in human urine samples. Furthermore, our developed dPAD constituted an accurate and effective device to precisely determine an Aβ protein concentration in real samples, with percentage recoveries in the range of 97-103%, and with the highest relative standard deviation of 5.41%. Subsequently, the validation of our assay was assessed by comparison with a commercial ELISA approach, with favorable results. Finally, the proposed dPAD was successfully applied to the determination of an Aβ protein in human urine samples and showed more benefits for the unskilled user, such as cost-efficiency, simplicity, low reagent usage, and low time consumption. It is also suitable for point-of-care monitoring. We report for the first time the development of a simple distance-based β-amyloid (Aβ) protein quantification on a paper-based device (dPAD) to screen and follow Alzheimer's disease (AD).